David Sable

David Sable MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund and Life Sciences Innovation Venture Capital funds. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was the founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015. After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds. Dr. Sable is an adjunct in the department of biology at Columbia University and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He serves on the board of directors for Hamilton Thorne Ltd, MedAnswers Inc, and Celmatix Inc, and is a clinical advisory board member and board observer for TMRW Life Sciences.